Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.90 USD

0.90
7,098,848

0.00 (-0.39%)

Updated May 3, 2024 04:00 PM ET

After-Market: $0.90 0.00 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Why Earnings Season Could Be Great for bluebird bio (BLUE)

by Zacks Equity Research

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Humana (HUM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Humana's (HUM) Q2 results are likely to reflect better revenues and membership growth.

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

Centene's (CNC) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Centene's (CNC) second-quarter results reflect robust revenues.

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

Anthem (ANTM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Anthem's (ANTM) second-quarter results are likely to reflect impressive revenues and rising membership.

Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Soleno (SLNO) to report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

How bluebird bio (BLUE) Stock Stands Out in a Strong Industry

by Zacks Equity Research

bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

bluebird Reports New Data on Betibeglogene Autotemcel for TDT

by Zacks Equity Research

bluebird (BLUE) reports new phase III data on betibeglogene autotemcel in TDT.

Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Global Blood Seeks Label Expansion of Oxbryta in Kids With SCD

by Zacks Equity Research

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

bluebird bio's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in bluebird bio.

Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

bluebird (BLUE): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA

by Zacks Equity Research

Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.

Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?